智通财经APP讯，新锐医药(06108)公布2024年业绩，收益约9390万港元，同比增加约87.1%。公司拥有人应占净亏损约为3100万港元，同比增加约39.6%。每股亏损1.86港仙。
公告称，收益增加主要由于集团于 2024年于中国推出医药化学试剂产品，其产生的毛利略低乃由于集团推出此产品尚处于起步阶段;及部分被集团主要产品二代头孢产品(1.0g)于本年度的需求下跌抵销，其原因为中国内地多个地区进一步加强采用抗菌药物分级分类管理政策，带来持续不利影响。故此，该产品于本年度的需求有所下跌。
亏损增加主要由于于接近到期日的滞销存货导致存货减值亏损约1310万港元(2023财政年度：减值亏损约160万港元);及部分被本年度拨备按公平值计入损益的金融资产公平值收益约390万港元(2023财政年度：公平值收益约40万港元)抵销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.